However, the role of ADCs in patients with gliomas has been reconsidered due to various factors, such as toxicity associated with targeting the EGFR family with certain cytotoxic payloads and the challenge of penetrating the blood–brain barrier to reach tumor cells [101,102]. This evidence concerns the gene EGFR and neoplasm.